• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (22)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pediatrics  • Pediatrics, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Joyce M. Lee, MD; Matthew M. Davis, MD, MAPP; Sarah J. Clark, MPH; Timothy P. Hofer, MD; Alex R. Kemper, MD, MPH, MS

Arch Pediatr Adolesc Med. 2006;160:263-269.

Objective  To estimate the cost-effectiveness of growth hormone (GH) therapy for idiopathic short stature (ISS).

Design  Cost-effectiveness analysis.

Setting  Decision model.

Patients  A cohort of 10-year-old prepubertal boys with ISS treated with GH.

Interventions  Comparison of children treated for 5 years with GH therapy vs children receiving no intervention.

Main Outcome Measures  Incremental cost per child, incremental growth per child, and incremental cost per inch of final height gain.

Results  The estimated incremental cost-effectiveness ratio of GH therapy for ISS in the base case analysis compared with no therapy was $52 634 per inch (per 2.54 cm), or $99 959 per child, reflecting an incremental growth of 1.9 in (4.8 cm). Alternate treatment strategies such as increased duration of GH treatment and high pubertal dosing of GH did not substantially improve the cost-effectiveness ratio. Probabilistic sensitivity analyses showed that growth variability in response to GH had the greatest impact on the cost-effectiveness of GH therapy.

Conclusions  Targeted treatment of children with ISS with the greatest potential for growth appears critical for maximizing cost-effectiveness of GH treatment. However, the significance of the cost per inch is difficult to judge until the utility gains associated with height gain after GH therapy for ISS can be ascertained.

Author Affiliations: Divisions of Pediatric Endocrinology (Dr Lee) and General Pediatrics (Drs Lee, Davis, and Kemper and Ms Clark), Child Health Evaluation and Research Unit (Drs Lee, Davis, and Kemper and Ms Clark), Gerald R. Ford School of Public Policy (Dr Davis), and Veterans Affairs Health Services Research and Development (Dr Hofer), University of Michigan, Ann Arbor.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Boosting the Late-Blooming Boy: Use of Growth-Promoting Agents in the Athlete With Constitutional Delay of Growth and Puberty
Curtis and Allen
Sports Health: A Multidisciplinary Approach 2011;3:32-40.
ABSTRACT | FULL TEXT  

Variation in Methods of Predicting Adult Height for Children With Idiopathic Short Stature
Topor et al.
Pediatrics 2010;126:938-944.
ABSTRACT | FULL TEXT  

A National Study of Physician Recommendations to Initiate and Discontinue Growth Hormone for Short Stature
Silvers et al.
Pediatrics 2010;126:468-476.
ABSTRACT | FULL TEXT  

Growth Hormone and Health Policy
Cuttler and Silvers
J. Clin. Endocrinol. Metab. 2010;95:3149-3153.
ABSTRACT | FULL TEXT  

Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin
Fuhr et al.
Eur J Endocrinol 2010;162:1051-1058.
ABSTRACT | FULL TEXT  

Growth monitoring
Hall et al.
Arch. Dis. Child. 2008;93:717-718.
FULL TEXT  

Gender of Pediatric Recombinant Human Growth Hormone Recipients in the United States and Globally
Grimberg et al.
J. Clin. Endocrinol. Metab. 2008;93:2050-2056.
ABSTRACT | FULL TEXT